Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein Source: Eur Respir J 2008; 31: 915-917 Year: 2008
Effects of n-3 polyunsaturated fatty acids on inflammatory markers in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 39s Year: 2006
The role of free fatty acids in idiopathic pulmonary fibrosis Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017
An application of omega-3 polyunsaturated fatty acids in treatment of COPD patients with pulmonary hypertension and chronic cor pulmonale Source: Eur Respir J 2001; 18: Suppl. 33, 251s Year: 2001
Is heart type fatty acid binding protein a marker of cardiac damage in patients with acute attacks of chronic obstructive pulmonary disease? Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008
Effectiveness of omega-3 polyunsaturated fatty acids in combination with acetylsalicylic acid in patients with COPD, complicated by cor pulmonale and the syndrome of blood hypercoagulation Source: Eur Respir J 2004; 24: Suppl. 48, 59s Year: 2004
Uric acid contributes to the progression of pulmonary hypertension in rodents and humans Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018
Heart-type fatty acid binding protein (H-FABP) and brain natriuretic peptide-fragment (BNP-fragment) in COPD patients with pneumonia Source: Annual Congress 2013 –COPD biomarkers Year: 2013
Relationship between OSA and non-alcoholic fatty liver disease Source: ERS Conference Year: 2015
The lipokine, or palmitoleic acid (16:1), is a biomarker of lung function in chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014
Non-alcoholic fatty liver disease (NAFLD): A new mechanism for co-morbidities in chronic obstructive pulmonary disease (COPD)? Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease Source: Eur Respir J, 49 (6) 1601923; 10.1183/13993003.01923-2016 Year: 2017
Vascular wall remodeling in patients with chronic thromboembolic pulmonary hypertension: a role for C-reactive protein Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008
Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 52S-63S Year: 2003
Dietary supplementation over one year with fatty acids reduces inflammatory markers and produces clinical improvement in adults with cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007
Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension}, Source: Eur Respir J 2012; 40: 886-894 Year: 2012
Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019 Year: 2019
Aging decreases reversibility of pulmonary fibrosis by regulating PRDM16-related fatty acid metabolism in lung fibroblasts Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021
Glucocorticoids correct fatty acids composition in asthma patients. Composition of fatty acids in high density lipoproteins in bronchitis patients Source: Eur Respir J 2007; 30: Suppl. 51, 145s Year: 2007
In sleep apnea patients nonalcoholic fatty liver disease (NAFLD) is associated with the severity of intermittent hypoxia and more severe endothelial dysfunction Source: Annual Congress 2012 - Sleep disorders in internal medicine Year: 2012